AbbVie Bets Big on Obesity and Neuroscience with Major U.S. Expansion

AbbVie commits $575M to build new US API facilities, boosting supply chain resilience for its next-gen neuroscience and obesity treatments, creating 300 jobs.

Pharmaceutical giant AbbVie is making a substantial commitment to its domestic manufacturing capabilities. A new multi-million dollar investment in the United States is laying the groundwork for the company's next generation of therapeutics, with a clear strategic focus on two of the industry's most lucrative growth sectors: neuroscience and obesity treatments.

Securing Strategic Independence Through Investment

This initiative is a key component of a broader strategy to scale up the internal production of active pharmaceutical ingredients (APIs). Including prior commitments, the total planned investment in the North Chicago area now reaches $575 million. The objective is to build more resilient supply chains for AbbVie's expanding pipeline in immunology, neuroscience, and oncology, while reinforcing the United States as a central pillar of its value chain.

To achieve this, approximately $380 million is allocated for the construction of two new manufacturing facilities at its North Chicago site. These plants are designed to incorporate cutting-edge production technologies and artificial intelligence to optimize the manufacture of highly complex drug substances. Construction is set to begin this spring and is expected to create about 300 new jobs in engineering and research fields.

Building Capacity for Future Blockbusters

The new facilities are projected to be fully operational by 2029. This long-term capacity planning secures AbbVie's ability to produce its upcoming generation of medicines and simultaneously reduces reliance on external manufacturing partners for critical ingredients. The move positions the company to more aggressively compete in the highly contested markets for neuroscience and obesity drugs.

On the Frankfurt stock exchange, AbbVie shares were quoted at €198.20 this past Friday, representing a slight decline of 1.15 percent. Despite this daily pullback, the stock has shown significant strength over a 30-day period, posting a notable gain of approximately 7.7 percent.